Since abnormal lipid metabolism is associated with the pathogenesis of metabolic diseases, ABC transporters participate in the inhibition of metabolic diseases, including AS, hypoalphalipoproteinemia (HA), coronary artery disease (CAD) and TD [13, 14]. This evidence concerns the gene ABCG2 and coronary artery disorder.